Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023
31 Julio 2023 - 7:00AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the
Company”), a clinical-stage biotechnology company developing novel
LAG-3 immunotherapies for cancer and autoimmune disease, today
announces that data from its TACTI-002 Phase II trial evaluating
the chemo-free combination of eftilagimod alpha (“efti”) and
KEYTRUDA® (pembrolizumab), MSD’s (Merck & Co., Rahway, NJ, USA)
anti-PD-1 therapy, in 1st line non-small cell lung cancer (1L
NSCLC) has been accepted for a Mini Oral presentation at the 2023
European Society for Medical Oncology (ESMO) Congress that will be
held in Madrid, Spain from 20-24 October 2023. The presentation
will include more mature overall survival data, following on from
the data announced on 17 May 2023.
Additionally, data from INSIGHT-003, an
investigator-initiated Phase I trial conducted by the Frankfurt
Institute of Clinical Cancer Research IKF evaluating efti in
conjunction with anti-PD-1 therapy (pembrolizumab) and doublet
chemotherapy (carboplatin/pemetrexed) in non-squamous 1L NSCLC, has
been accepted for a poster presentation. Also, a Trial in Progress
poster for the EFTISARC-NEO investigator-initiated Phase II trial
evaluating efti with pembrolizumab and radiotherapy in soft tissue
sarcoma will be presented.
Oral PresentationTitle:
Combining the antigen-presenting cell activator eftilagimod alpha
(soluble LAG-3) and pembrolizumab: overall survival data from the
1st line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002
(Phase II)
- Presenter: Dr. Enric Carcereny,
Catalan Institute of Oncology, Badalona (ICO)
- Date and Time: Saturday, October
21, 2023; 9:05 AM CEST
- Session: Mini Oral session,
1312MO
- Abstract ID: (#2174)
Poster
PresentationsTitle: INSIGHT 003
evaluating feasibility of eftilagimod alpha (soluble LAG-3)
combined with 1st line chemo-immunotherapy in metastatic non-small
cell lung cancer (NSCLC) adenocarcinomas
Title: Pembrolizumab in combination with
eftilagimod alpha and radiotherapy in neoadjuvant treatment of
patients with soft tissue sarcomas – EFTISARC-NEO trial
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,
Rahway, NJ, USA.
About Eftilagimod Alpha
(Efti)Efti is Immutep’s proprietary soluble LAG-3 protein
and MHC Class II agonist that stimulates both innate and adaptive
immunity for the treatment of cancer. As a first-in-class antigen
presenting cell (APC) activator, efti binds to MHC (major
histocompatibility complex) Class II molecules on APC leading to
activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper
T cells, dendritic cells, NK cells, and monocytes. It also
upregulates the expression of key biological molecules like IFN-ƴ
and CXCL10 that further boost the immune system’s ability to fight
cancer.
Efti is under evaluation for a variety of solid
tumours including non-small cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its
favourable safety profile enables various combinations, including
with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has
received Fast Track Designation in 1st line HNSCC and in 1st line
NSCLC from the United States Food and Drug Administration
(FDA).
About ImmutepImmutep is a
clinical stage biotechnology company developing novel LAG-3
immunotherapy for cancer and autoimmune disease. We are pioneers in
the understanding and advancement of therapeutics related to
Lymphocyte Activation Gene-3 (LAG-3), and our diversified product
portfolio harnesses its unique ability to stimulate or suppress the
immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to
maximise value for shareholders. For more information, please visit
www.immutep.com.
Australian
Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406
759 268; cstrong@citadelmagnus.com
U.S.
Investors/Media:Chris Basta, VP,
Investor Relations and Corporate Communications+1 (631) 318 4000;
chris.basta@immutep.com
Immutep (NASDAQ:IMMP)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Immutep (NASDAQ:IMMP)
Gráfica de Acción Histórica
De May 2023 a May 2024